Published in Cell on July 14, 1989
HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J (1990) 9.34
Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc Natl Acad Sci U S A (1990) 6.85
Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol (1992) 6.77
Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci U S A (1991) 6.58
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol (1997) 5.73
Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol (1991) 5.49
Retroviral integrase domains: DNA binding and the recognition of LTR sequences. Nucleic Acids Res (1991) 4.39
Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage. J Virol (1991) 3.89
Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J (2006) 3.68
Substrate specificity of recombinant human immunodeficiency virus integrase protein. J Virol (1991) 3.63
Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J (2001) 3.60
Mutational analysis of the integrase protein of human immunodeficiency virus type 2. Proc Natl Acad Sci U S A (1992) 3.55
Complementation between HIV integrase proteins mutated in different domains. EMBO J (1993) 3.32
Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations. J Virol (1993) 3.28
Site-specific hydrolysis and alcoholysis of human immunodeficiency virus DNA termini mediated by the viral integrase protein. Nucleic Acids Res (1991) 2.93
DNA binding properties of the integrase proteins of human immunodeficiency viruses types 1 and 2. Nucleic Acids Res (1991) 2.74
Fv-1 restriction and its effects on murine leukemia virus integration in vivo and in vitro. J Virol (1992) 2.40
Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication. J Virol (1994) 2.37
Removal of 3'-OH-terminal nucleotides from blunt-ended long terminal repeat termini by the avian retrovirus integration protein. J Virol (1990) 2.25
Sequence of the circle junction of human immunodeficiency virus type 1: implications for reverse transcription and integration. J Virol (1990) 2.24
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol (1995) 2.22
Protection of retroviral DNA from autointegration: involvement of a cellular factor. Proc Natl Acad Sci U S A (1994) 2.20
A mutation at one end of Moloney murine leukemia virus DNA blocks cleavage of both ends by the viral integrase in vivo. J Virol (1992) 2.18
Overlapping retrovirus U5 sequence elements are required for efficient integration and initiation of reverse transcription. J Virol (1991) 2.16
The phage Mu transpososome core: DNA requirements for assembly and function. EMBO J (1995) 2.14
Marked infidelity of human immunodeficiency virus type 1 reverse transcriptase at RNA and DNA template ends. Proc Natl Acad Sci U S A (1994) 2.12
Sequence requirements for integration of Moloney murine leukemia virus DNA in vitro. J Virol (1990) 2.06
Human immunodeficiency virus type 1 integration protein: DNA sequence requirements for cleaving and joining reactions. J Virol (1992) 2.02
Relationship of avian retrovirus DNA synthesis to integration in vitro. Mol Cell Biol (1991) 1.92
An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences. J Virol (1994) 1.81
Analysis of long terminal repeat circle junctions of human immunodeficiency virus type 1. J Virol (1990) 1.80
Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis. Nucleic Acids Res (1993) 1.79
Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events. J Virol (1990) 1.78
Analysis of mutations in the integration function of Moloney murine leukemia virus: effects on DNA binding and cutting. J Virol (1990) 1.75
Concerted integration of viral DNA termini by purified avian myeloblastosis virus integrase. J Virol (1992) 1.74
Concerted integration of linear retroviral DNA by the avian sarcoma virus integrase in vitro: dependence on both long terminal repeat termini. J Virol (1996) 1.72
Transfer RNA genes are genomic targets for de Novo transposition of the yeast retrotransposon Ty3. Genetics (1990) 1.67
Genetic analysis of homomeric interactions of human immunodeficiency virus type 1 integrase using the yeast two-hybrid system. Proc Natl Acad Sci U S A (1993) 1.65
Retroviral DNA integration. Microbiol Mol Biol Rev (1999) 1.64
Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesis. J Virol (1999) 1.64
Defining nucleic acid-binding properties of avian retrovirus integrase by deletion analysis. J Virol (1991) 1.62
Integration of human immunodeficiency virus DNA: adduct interference analysis of required DNA sites. Proc Natl Acad Sci U S A (1992) 1.52
Integration of human immunodeficiency virus types 1 and 2 DNA in vitro by cytoplasmic extracts of Moloney murine leukemia virus-infected mouse NIH 3T3 cells. J Virol (1990) 1.50
Asymmetric processing of human immunodeficiency virus type 1 cDNA in vivo: implications for functional end coupling during the chemical steps of DNA transposition. Mol Cell Biol (2001) 1.49
Human immunodeficiency virus type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. J Virol (1993) 1.46
Plus-strand origin for human immunodeficiency virus type 1: implications for integration. J Virol (1990) 1.45
Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates. J Virol (1994) 1.45
Circular DNA of human immunodeficiency virus: analysis of circle junction nucleotide sequences. J Virol (1991) 1.44
Specific and independent recognition of U3 and U5 att sites by human immunodeficiency virus type 1 integrase in vivo. J Virol (1998) 1.42
Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions. J Virol (1998) 1.40
Unusual features of integrated cDNAs generated by infection with genome-free retroviruses. Mol Cell Biol (1990) 1.32
Characterization of the block in replication of nucleocapsid protein zinc finger mutants from moloney murine leukemia virus. J Virol (1999) 1.32
The karyophilic properties of human immunodeficiency virus type 1 integrase are not required for nuclear import of proviral DNA. J Virol (2000) 1.27
Comparison of DNA binding and integration half-site selection by avian myeloblastosis virus integrase. J Virol (1993) 1.26
Role of the His-Cys finger of Moloney murine leukemia virus integrase protein in integration and disintegration. J Virol (1993) 1.25
Molecular requirements for human immunodeficiency virus type 1 plus-strand transfer: analysis in reconstituted and endogenous reverse transcription systems. J Virol (1999) 1.22
An antibody that binds the immunoglobulin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells. EMBO J (1993) 1.22
Mutational analysis of the carboxyl terminus of the Moloney murine leukemia virus integration protein. J Virol (1991) 1.21
Requirement for a conserved serine in both processing and joining activities of retroviral integrase. Proc Natl Acad Sci U S A (1992) 1.20
Retroviral integrase proteins and HIV-1 DNA integration. J Biol Chem (2012) 1.20
Host proteins interacting with the Moloney murine leukemia virus integrase: multiple transcriptional regulators and chromatin binding factors. Retrovirology (2008) 1.20
DNA substrate requirements for different activities of the human immunodeficiency virus type 1 integrase protein. J Virol (1994) 1.15
Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob Agents Chemother (1995) 1.15
Different roles of bases within the integration signal sequence of human immunodeficiency virus type 1 in vitro. J Virol (1995) 1.15
Efficient retroviral infection of mammalian cells is blocked by inhibition of poly(ADP-ribose) polymerase activity. J Virol (1996) 1.15
Sequence-specific binding of DNA by the Moloney murine leukemia virus integrase protein. J Virol (1990) 1.14
The application of a homologous recombination assay revealed amino acid residues in an LTR-retrotransposon that were critical for integration. J Virol (1998) 1.13
Characterization of Moloney murine leukemia virus p12 mutants blocked during early events of infection. J Virol (2002) 1.13
Rapid microtiter assays for poxvirus topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: application to inhibitor isolation. Nucleic Acids Res (2000) 1.10
Mapping viral DNA specificity to the central region of integrase by using functional human immunodeficiency virus type 1/visna virus chimeric proteins. J Virol (1998) 1.09
Juxtaposition of two viral DNA ends in a bimolecular disintegration reaction mediated by multimers of human immunodeficiency virus type 1 or murine leukemia virus integrase. J Virol (1994) 1.08
Deciphering the code for retroviral integration target site selection. PLoS Comput Biol (2010) 1.06
Mutations in the U5 sequences adjacent to the primer binding site do not affect tRNA cleavage by rous sarcoma virus RNase H but do cause aberrant integrations in vivo. J Virol (2006) 1.05
3'-end processing and kinetics of 5'-end joining during retroviral integration in vivo. J Virol (1997) 1.04
Characterization of recombinant murine leukemia virus integrase. J Virol (1995) 1.03
Functional identification of nucleotides conferring substrate specificity to retroviral integrase reactions. J Virol (1997) 1.02
Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J Comput Aided Mol Des (2005) 1.02
Sequences in the human immunodeficiency virus type 1 U3 region required for in vivo and in vitro integration. J Virol (1995) 1.02
The sequence of human immunodeficiency virus type 2 circle junction suggests that integration protein cleaves the ends of linear DNA asymmetrically. J Virol (1991) 1.02
Human immunodeficiency virus type 1 DNA integration: fine structure target analysis using synthetic oligonucleotides. J Virol (1993) 1.01
Effect of polypurine tract (PPT) mutations on human immunodeficiency virus type 1 replication: a virus with a completely randomized PPT retains low infectivity. J Virol (2005) 1.01
Conserved residues Pro-109 and Asp-116 are required for interaction of the human immunodeficiency virus type 1 integrase protein with its viral DNA substrate. J Virol (1993) 1.01
Functional domains of Moloney murine leukemia virus integrase defined by mutation and complementation analysis. J Virol (1996) 1.01
Mutations in nonconserved domains of Ty3 integrase affect multiple stages of the Ty3 life cycle. J Virol (1999) 1.00
Retracted Moloney murine leukemia virus integration protein produced in yeast binds specifically to viral att sites. J Virol (1990) 0.99
Posttranscriptional modification of retroviral primers is required for late stages of DNA replication. Proc Natl Acad Sci U S A (1997) 0.99
In vivo Ty1 reverse transcription can generate replication intermediates with untidy ends. J Virol (1998) 0.98
Influence of substrate structure on disintegration activity of Moloney murine leukemia virus integrase. J Virol (1993) 0.97
RNase H requirements for the second strand transfer reaction of human immunodeficiency virus type 1 reverse transcription. J Virol (1999) 0.97
Ty3 integrase mutants defective in reverse transcription or 3'-end processing of extrachromosomal Ty3 DNA. J Virol (1996) 0.96
Human immunodeficiency virus type 2 preintegration complexes: activities in vitro and response to inhibitors. J Virol (1997) 0.95
Key determinants of target DNA recognition by retroviral intasomes. Retrovirology (2015) 0.93
Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity. J Virol (1996) 0.92
A novel function for spumaretrovirus integrase: an early requirement for integrase-mediated cleavage of 2 LTR circles. Retrovirology (2005) 0.92
Retroviral DNA Integration. Chem Rev (2016) 0.90
Characterization of a replication-defective human immunodeficiency virus type 1 att site mutant that is blocked after the 3' processing step of retroviral integration. J Virol (2000) 0.90
Rapid solution assays for retroviral integration reactions and their use in kinetic analyses of wild-type and mutant Rous sarcoma virus integrases. Proc Natl Acad Sci U S A (1993) 0.90
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell (1993) 7.34
Construction and analysis of deletion mutations in the pol gene of Moloney murine leukemia virus: a new viral function required for productive infection. Cell (1984) 7.16
Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J (1996) 6.36
Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol (1988) 6.31
A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J Virol (1985) 5.78
Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell (1980) 5.68
PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature (2000) 5.48
Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science (1994) 5.47
Characterization of Moloney murine leukemia virus mutants with single-amino-acid substitutions in the Cys-His box of the nucleocapsid protein. J Virol (1989) 5.47
The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell (1994) 5.00
Sequence and spacing requirements of a retrovirus integration site. J Mol Biol (1988) 4.89
RNA packaging. Curr Top Microbiol Immunol (1996) 4.88
Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell (1999) 4.55
Physical and genetic characterization of deletion mutants of simian virus 40 constructed in vitro. J Virol (1977) 4.23
Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. J Virol (1993) 4.22
Mutants and pseudorevertants of Moloney murine leukemia virus with alterations at the integration site. Cell (1985) 3.81
Intramolecular integration within Moloney murine leukemia virus DNA. J Virol (1981) 3.77
Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. EMBO J (1999) 3.67
Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol (2001) 3.66
Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity (1995) 3.37
Specific binding of human immunodeficiency virus type 1 gag polyprotein and nucleocapsid protein to viral RNAs detected by RNA mobility shift assays. J Virol (1993) 3.15
Mutations in the gag gene of Moloney murine leukemia virus: effects on production of virions and reverse transcriptase. J Virol (1984) 3.14
Deletion mutants of Moloney murine leukemia virus which lack glycosylated gag protein are replication competent. J Virol (1983) 3.04
Domain structure of the Moloney murine leukemia virus reverse transcriptase: mutational analysis and separate expression of the DNA polymerase and RNase H activities. Proc Natl Acad Sci U S A (1988) 3.02
Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein. J Virol (1991) 3.00
Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses. J Virol (2000) 2.98
Germ-line transmission of a c-abl mutation produced by targeted gene disruption in ES cells. Science (1989) 2.90
Lethal effect of the Abelson murine leukemia virus transforming gene product. Cell (1981) 2.82
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
Expression of the gag-pol fusion protein of Moloney murine leukemia virus without gag protein does not induce virion formation or proteolytic processing. J Virol (1988) 2.74
Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev (1992) 2.72
Construction and analysis of deletion mutations in the U5 region of Moloney murine leukemia virus: effects on RNA packaging and reverse transcription. J Virol (1989) 2.69
Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. J Virol (1994) 2.68
The Drosophila snr1 and brm proteins are related to yeast SWI/SNF proteins and are components of a large protein complex. Mol Biol Cell (1995) 2.67
Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus. J Virol (1999) 2.61
Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol (1995) 2.56
Conferring RNA polymerase activity to a DNA polymerase: a single residue in reverse transcriptase controls substrate selection. Proc Natl Acad Sci U S A (1997) 2.54
Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polyproteins during RNA packaging in vivo. J Virol (1995) 2.52
Adaptation of a retrovirus as a eucaryotic vector transmitting the herpes simplex virus thymidine kinase gene. Mol Cell Biol (1982) 2.51
Specificity and sequence requirements for interactions between various retroviral Gag proteins. J Virol (1994) 2.50
Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science (1999) 2.45
Assays for retroviral reverse transcriptase. Methods Enzymol (1995) 2.43
Selective regulation of integrin--cytoskeleton interactions by the tyrosine kinase Src. Nat Cell Biol (1999) 2.41
Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc. Science (1993) 2.40
Isolation of a recombinant murine leukemia virus utilizing a new primer tRNA. J Virol (1986) 2.33
The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol (1996) 2.31
Mutations in gag proteins P12 and P15 of Moloney murine leukemia virus block early stages of infection. J Virol (1984) 2.30
Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci U S A (2001) 2.29
Role for the target enzyme in deactivation of photoreceptor G protein in vivo. Science (1998) 2.29
The palindromic LTR-LTR junction of Moloney murine leukemia virus is not an efficient substrate for proviral integration. J Virol (1989) 2.27
Construction of hybrid viruses containing SV40 and lambda phage DNA segments and their propagation in cultured monkey cells. Cell (1976) 2.25
Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol Cell Biol (1996) 2.23
Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase. Structure (1995) 2.20
Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell (1991) 2.19
A mutation at one end of Moloney murine leukemia virus DNA blocks cleavage of both ends by the viral integrase in vivo. J Virol (1992) 2.18
Analysis of retroviral pol gene products with antisera raised against fusion proteins produced in Escherichia coli. J Virol (1986) 2.18
Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase. Science (1996) 2.11
Expression of enzymatically active reverse transcriptase in Escherichia coli. Proc Natl Acad Sci U S A (1985) 2.11
Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development (2000) 2.10
Linker insertion mutagenesis of the human immunodeficiency virus reverse transcriptase expressed in bacteria: definition of the minimal polymerase domain. Proc Natl Acad Sci U S A (1989) 2.06
Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol (2000) 2.06
Construction of mutants of Moloney murine leukemia virus by suppressor-linker insertional mutagenesis: positions of viable insertion mutations. Proc Natl Acad Sci U S A (1984) 2.05
Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev (1995) 2.04
Purification and characterization of murine retroviral reverse transcriptase expressed in Escherichia coli. J Biol Chem (1985) 2.02
5' regions of HIV-1 RNAs are not sufficient for encapsidation: implications for the HIV-1 packaging signal. Virology (1995) 1.95
Transfection of fibroblasts by cloned Abelson murine leukemia virus DNA and recovery of transmissible virus by recombination with helper virus. J Virol (1982) 1.90
Reverse transcription of retroviral genomes: mutations in the terminal repeat sequences. J Virol (1985) 1.90
Analysis of binding elements in the human immunodeficiency virus type 1 genomic RNA and nucleocapsid protein. Virology (1994) 1.88
Point mutations in the P30 domain of the gag gene of Moloney murine leukemia virus. Virology (1985) 1.85
Expression of reverse transcriptase activity of human T-lymphotropic virus type III (HTLV-III/LAV) in Escherichia coli. J Virol (1986) 1.84
Insertion mutagenesis of embryonal carcinoma cells by retroviruses. Science (1985) 1.82
Construction and recovery of viable retroviral genomes carrying a bacterial suppressor transfer RNA gene. Science (1985) 1.77
Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J Virol (1995) 1.77
Analysis of mutations in the integration function of Moloney murine leukemia virus: effects on DNA binding and cutting. J Virol (1990) 1.75
Genetic assay for multimerization of retroviral gag polyproteins. J Virol (1992) 1.74
Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells. J Virol (1981) 1.73
Isolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1991) 1.73
Analysis of mutations in the envelope gene of Moloney murine leukemia virus: separation of infectivity from superinfection resistance. Virology (1991) 1.73
Structure of a cloned circular retroviral DNA containing a tRNA sequence between the terminal repeats. J Virol (1986) 1.72
Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem (1999) 1.68
Gene product of Moloney murine leukemia virus required for proviral integration is a DNA-binding protein. J Mol Biol (1988) 1.67
Abortive reverse transcription by mutants of Moloney murine leukemia virus deficient in the reverse transcriptase-associated RNase H function. J Virol (1991) 1.66
Genetic analysis of homomeric interactions of human immunodeficiency virus type 1 integrase using the yeast two-hybrid system. Proc Natl Acad Sci U S A (1993) 1.65
Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol (1996) 1.64
Mutation of Tec family kinases alters T helper cell differentiation. Nat Immunol (2001) 1.63
Mutants of murine leukemia viruses and retroviral replication. Biochim Biophys Acta (1987) 1.57
Nuclease activities of Moloney murine leukemia virus reverse transcriptase. Mutants with altered substrate specificities. J Biol Chem (1993) 1.54
Infection of nondividing cells by Rous sarcoma virus. J Virol (2001) 1.53
Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat Genet (2000) 1.51
Amino acid substitutions in the CA protein of Moloney murine leukemia virus that block early events in infection. Virology (1996) 1.47
Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection. Mol Biol Cell (1999) 1.47
Cellular motor protein KIF-4 associates with retroviral Gag. J Virol (1999) 1.43
High-frequency disruption of the N-myc gene in embryonic stem and pre-B cell lines by homologous recombination. Mol Cell Biol (1990) 1.43
Tec family kinases modulate thresholds for thymocyte development and selection. J Exp Med (2000) 1.41
RNase H domain mutations affect the interaction between Moloney murine leukemia virus reverse transcriptase and its primer-template. Proc Natl Acad Sci U S A (1993) 1.41
Defects in Moloney murine leukemia virus replication caused by a reverse transcriptase mutation modeled on the structure of Escherichia coli RNase H. J Virol (1992) 1.41
Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene (1997) 1.38
Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria. J Virol (1993) 1.37
Targeted gene disruption of the endogenous c-abl locus by homologous recombination with DNA encoding a selectable fusion protein. Proc Natl Acad Sci U S A (1990) 1.37
Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci U S A (2001) 1.36